Literature DB >> 26738536

Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Andreas Willerslev-Olsen1, Thorbjørn Krejsgaard1, Lise M Lindahl2, Ivan V Litvinov3, Simon Fredholm1, David L Petersen1, Claudia Nastasi1, Robert Gniadecki4, Nigel P Mongan5, Denis Sasseville6, Mariusz A Wasik7, Charlotte M Bonefeld1, Carsten Geisler1, Anders Woetmann1, Lars Iversen2, Mogens Kilian8, Sergei B Koralov9, Niels Odum1.   

Abstract

Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation of malignant T cells in a chronic inflammatory environment. With disease progression, bacteria colonize the compromised skin barrier and half of CTCL patients die of infection rather than from direct organ involvement by the malignancy. Clinical data indicate that bacteria play a direct role in disease progression, but little is known about the mechanisms involved. Here, we demonstrate that bacterial isolates containing staphylococcal enterotoxin A (SEA) from the affected skin of CTCL patients, as well as recombinant SEA, stimulate activation of signal transducer and activator of transcription 3 (STAT3) and upregulation of interleukin (IL)-17 in immortalized and primary patient-derived malignant and nonmalignant T cells. Importantly, SEA induces STAT3 activation and IL-17 expression in malignant T cells when cocultured with nonmalignant T cells, indicating an indirect mode of action. In accordance, malignant T cells expressing an SEA-nonresponsive T-cell receptor variable region β chain are nonresponsive to SEA in monoculture but display strong STAT3 activation and IL-17 expression in cocultures with SEA-responsive nonmalignant T cells. The response is induced via IL-2 receptor common γ chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T cells, and blocked by tofacitinib, a clinical-grade JAK3 inhibitor. In conclusion, we demonstrate that SEA induces cell cross talk-dependent activation of STAT3 and expression of IL-17 in malignant T cells, suggesting a mechanism whereby SEA-producing bacteria promote activation of an established oncogenic pathway previously implicated in carcinogenesis.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26738536      PMCID: PMC4786838          DOI: 10.1182/blood-2015-08-662353

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  76 in total

1.  Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Marieke A van Leeuwen; Janneke N Samsom; Rein Willemze; Cornelis P Tensen; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2011-09-22       Impact factor: 8.551

Review 2.  Histopathology and genetics of cutaneous T-cell lymphoma.

Authors:  Bruce R Smoller; Marco Santucci; Gary S Wood; Sean J Whittaker
Journal:  Hematol Oncol Clin North Am       Date:  2003-12       Impact factor: 3.722

3.  IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.

Authors:  Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Agnieszka Witkiewicz; Puthiyaveettil N Raghunath; Mouna El-Salem; Erle Robertson; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

4.  STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.

Authors:  C Brender; M Nielsen; K Kaltoft; G Mikkelsen; Q Zhang; M Wasik; N Billestrup; N Odum
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

5.  Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system.

Authors:  Emmilia Hodak; Tirza Klein; Boaz Gabay; Dan Ben-Amitai; Reuven Bergman; Michael Gdalevich; Meora Feinmesser; Lea Maron; Michael David
Journal:  J Am Acad Dermatol       Date:  2005-03       Impact factor: 11.527

Review 6.  Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2011-11       Impact factor: 10.047

7.  A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.

Authors:  Georgia Levidou; Marina Siakantaris; Theodora Papadaki; Evangelia Papadavid; Theodoros P Vassilakopoulos; Maria K Angelopoulou; Leonidas Marinos; Vassiliki Nikolaou; Aphroditi Economidi; Christina Antoniou; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  J Am Acad Dermatol       Date:  2013-05-16       Impact factor: 11.527

8.  Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

Authors:  Nina A Sibbesen; Katharina L Kopp; Ivan V Litvinov; Lars Jønson; Andreas Willerslev-Olsen; Simon Fredholm; David L Petersen; Claudia Nastasi; Thorbjørn Krejsgaard; Lise M Lindahl; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Lars Iversen; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Oncotarget       Date:  2015-08-21

9.  STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.

Authors:  Navin K Verma; Anthony M Davies; Aideen Long; Dermot Kelleher; Yuri Volkov
Journal:  Cell Mol Biol Lett       Date:  2010-03-05       Impact factor: 5.787

10.  Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.

Authors:  Katia Boniface; Kristian S Bak-Jensen; Ying Li; Wendy M Blumenschein; Mandy J McGeachy; Terrill K McClanahan; Brent S McKenzie; Robert A Kastelein; Daniel J Cua; René de Waal Malefyt
Journal:  J Exp Med       Date:  2009-03-09       Impact factor: 14.307

View more
  33 in total

1.  Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Authors:  Pamela B Allen; Jeffrey Switchenko; Amy Ayers; Esther Kim; Mary Jo Lechowicz
Journal:  Leuk Lymphoma       Date:  2020-06-19

Review 2.  Antidromic neurogenic activity and cutaneous bacterial flora.

Authors:  Marc G J Feuilloley
Journal:  Semin Immunopathol       Date:  2018-03-16       Impact factor: 9.623

3.  Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.

Authors:  Lise M Lindahl; Andreas Willerslev-Olsen; Lise M R Gjerdrum; Pia R Nielsen; Edda Blümel; Anne H Rittig; Pamela Celis; Bjorn Herpers; Jürgen C Becker; Birgitte Stausbøl-Grøn; Mariusz A Wasik; Maria Gluud; Simon Fredholm; Terkild B Buus; Claus Johansen; Claudia Nastasi; Lukas Peiffer; Linda Kubat; Michael Bzorek; Jens O Eriksen; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Carsten Geisler; Tomas Mustelin; Erik Langhoff; Michael Givskov; Anders Woetmann; Mogens Kilian; Thomas Litman; Lars Iversen; Niels Odum
Journal:  Blood       Date:  2019-07-22       Impact factor: 22.113

Review 4.  Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy.

Authors:  Ivan V Litvinov; Anna Shtreis; Kenneth Kobayashi; Steven Glassman; Matthew Tsang; Anders Woetmann; Denis Sasseville; Niels Ødum; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2016-06-06       Impact factor: 8.110

5.  Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.

Authors:  Jianqiang Wu; Gary S Wood
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

6.  Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.

Authors:  Philippe Lefrançois; Pingxing Xie; Linghua Wang; Michael T Tetzlaff; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Nathalie Provost; Martin Gilbert; Xiao Ni; Denis Sasseville; David A Wheeler; Madeleine Duvic; Ivan V Litvinov
Journal:  Oncoimmunology       Date:  2018-05-31       Impact factor: 8.110

7.  Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.

Authors:  Christina A Del Guzzo; Arsenije Kojadinovic; Ravi R Vinnakota; Larisa J Geskin; Jessica C Newman; Erik Langhoff; Yeun-Hee A Park; Susan E Bates; Ali N Dana
Journal:  Oncologist       Date:  2021-05-14

Review 8.  The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication.

Authors:  Joseph S Durgin; David M Weiner; Maria Wysocka; Alain H Rook
Journal:  J Am Acad Dermatol       Date:  2020-12-22       Impact factor: 11.527

9.  MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.

Authors:  Lise M Lindahl; Maria Gluud; Thomas Emmanuel; Emil A Thomsen; Tengpeng Hu; Anne H Rittig; Pamela Celis; Veronica Stolearenco; Thorbjørn Krejsgaard; Claus Johansen; Andreas Willerslev-Olsen; Terkild B Buus; Anders Woetmann; Lars Aagaard; Carsten Geisler; Thomas Litman; Jacob G Mikkelsen; Niels Odum; Lars Iversen
Journal:  Acta Derm Venereol       Date:  2020-09-30       Impact factor: 3.875

10.  Dysregulated Expression of Antimicrobial Peptides in Skin Lesions of Patients with Cutaneous T-cell Lymphoma.

Authors:  Ulrike Wehkamp; Marion Jost; Kai Wehkamp; Jürgen Harder
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.